Apple Health PDL Drug Policy Motions



Antihyperlipidemics – Proprotein Convertase Subtilisin Kexin Type 9 (PCSK-9) Inhibitors

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 39.35.00-3 as recommended.

Motion: Storhaug

□ 2nd: Lee

